Novel Type of Immune Cell Discovered in Type 1 Diabetes Patients

A rogue hybrid lymphocyte, bearing characteristics of both B and T cells, may play a role in driving autoimmunity in the disease, although the mechanism is far from clear.

Written byKatarina Zimmer
| 6 min read
x lymphocyte DE cell immune immunology t cell b cell type 1 diabetes

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

ABOVE: Colorized scanning electron micrographs of B and T lymphocytes (left, right) shown with a fluorescent microscopy image of the newly discovered DE cell, also called the X cell to denote its crossover nature between B cells and T cells (center).
B AND T CELL IMAGES FROM THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; X CELL IMAGE FROM JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

According to textbooks, cells of the adaptive immune system must be either B cells or T cells—they can’t be both, or anything in between. But proving once again that nature is full of surprises, scientists have now discovered a novel type of lymphocyte in type 1 diabetes patients that combines characteristics of B cells and T cells. The researchers suggest that these hybrids could play an important role in the disease by encouraging the immune system to attack the body’s own insulin-producing cells, they report today ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies